Inotersen (Tegsedi®) is indicated for the treatment of Stage 1 or Stage 2 polyneuropathy in adult patients with hereditary transthyretin (TTR) amyloidosis (hATTR).
|NCPE Assessment Process||Ongoing|
|Rapid review commissioned||26/08/2019|
|Rapid review completed||07/10/2019|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of inotersen compared with the current standard of care.|